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Introduction. Previously we proposed a cellular imaging technique to determine the surviving fraction of transplanted cells in
vivo. Epicardial kinetics using Indium-111 determined the Debris Impulse Response Function (DIRF) and leakage coeﬃcient
parameters. Convolution-based modeling which corrected for these signal contributions indicated that 111In activity was
quantitative of cell viability with half-lives within 20hrs to 37 days. We determine if the 37-day upper limit remains valid for
endocardial injections by comparing previous epicardial cell leakage parameter estimates to those for endocardial cells. Methods.
Normalcaninemyocardiumwasinjected (111In-tropolone)epicardially (9injections)orendocardially(10injections).Continuous
whole body and SPECT scans for 5 hours were acquired with three weekly follow-up imaging sessions up to 20–26 days. Time-
activity curves evaluated each injection type. Results. The epicardial and endocardial kinetics were not signiﬁcantly diﬀerent (Epi:
1286 ± 253; Endo: 1567 ± 470 hours P = .62). Conclusion. The original epicardial estimate of leakage kinetics has been validated
for use in endocardial injections.
1.Introduction
Apart from the long-term impact stem cells can have on
the myocardium of the infarcted heart [1–3], progression
in stem cell imaging requires an understanding of viability
and function of the transplanted cells soon after transplan-
tation. Some of the advancements in preclinical imaging
technologies, namely, reporter gene imaging, to interrogate
the status of transplanted cells [4, 5] cannot be currently
applied clinically due to safety concerns related to injecting
c e l l sw i t hf o r e i g nD N A .H o w e v e r ,t ot h i se n d ,o u rg r o u p
has reported on a SPECT cellular imaging technique using
a clinically available radiotracer to determine the viability
of transplanted cells as a function of time in a large animal
model of acute myocardial infarction [6].
The basis of this technique is the radiotracer Indium-111
and its associated clearance kinetics in canine myocardium
under diﬀerent conditions. 111In (chelated with oxine,
tropolone, etc. for in vitro cell labeling) is an FDA approved
radiotracer [7] and is used in clinical infection imaging
where white blood cells are radiolabeled ex vivo using the
chelator, and reinjected cells localize to sites of infection
and/or inﬂammation [8]. For the use of this tracer for imag-
ing transplanted cells, in vivo acquired parameters called the
leakage coeﬃcient (C) and DIRF (Debris Impulse Response
Function) are obtained to estimate the clearance half-lives
of transplanted cells that can be measured from the SPECT
signal. Using a convolution-based method, both parameters
are used to derive the SPECT signal associated with viable2 International Journal of Molecular Imaging
cells only and constitute the upper (leakage coeﬃcient)
and lower (DIRF) bounds within which this method of
estimating viable transplanted cell half-life is valid. While
DIRF reﬂects the function by which 111In-labeled cytosolic
proteins are cleared from the interstitial compartment of the
myocardium (normal and infarcted) for example, cell death,
an assumption in this method is that all interstitial 111In is
removed according to DIRF regardless of the mechanism by
which it enters this compartment. Similarly, C reﬂects the
rate of 111In loss from radiolabeled cells into the interstitium
as a result of cellular processes unrelated to cell death, which
according to the aforementioned assumption, is then cleared
from the myocardium according to DIRF. These upper and
lower bounds then stipulate that if clearance half-lives of
transplanted 111In-labeledcellsarefasterorslowerthanDIRF
or C, respectively, the model cannot be applied to derive the
transplanted cell half-life.
Further in vitro work established the stability of 111In
in the cell population of interest and the inability of 111In
released from dead or viable cells to be resequestered by
other cells modeling the surrounding myocardium. In vivo
imaging with 111In established a correction curve whereby
the measured SPECT signal from labeled cells transplanted
into the myocardium could be used to estimate and remove
111In located outside viable cells generating a new biological
half-life associated with viable cells. Finally, our group
proposed a patient imaging protocol for clinical application
of this technique [6].
Given that cell number at targeted locationscan correlate
withtherapeuticbeneﬁt[9,10],directintramyocardial injec-
tions of cells have shown higher relative retention [11]a n d
is likely the preferred method for larger cells. For example,
mesenchymal cells can plug capillaries when administered
via the intracoronary route [12] resulting in microinfarction
in canines [13]. Our cellular imaging method was tested
using the stromal fraction of adult canine bone marrow
administeredthroughepicardialinjection,which issurgically
invasive and not likely to be used in routine clinical practice.
As an alternative approach, however, endocardial catheter
transplantation of cells would be a bettersolutionfor clinical
cell transplantation and provides the option of multiple
transplants over time. Importantly, diﬀerences in perfusion
and intramyocardial pressures between the subepicardium
and subendocardium in canine myocardium lead to trans-
mural gradients [14, 15]. Retention of injected material
may be inﬂuenced by the cyclical beat-to-beat changes in
intramyocardial pressures with resultant loss of the injected
materialthroughneedletracks[16].Reducingthissigniﬁcant
initial loss will be instrumental in improving cell retention.
Hence the forces that inﬂuence cell loss for an epicardial
injection, in theory, would be diﬀerent than those aﬀecting
an epicardial injection thus aﬀecting clearance kinetics.
The aim ofthispaperistovalidatethatthemodelleakage
parameter for endocardial injections is similar to epicardial
injections and comparatively evaluate the eﬃciency of the
endocardial injection. This would allow wider application
of the developed model as endocardial injections, from a
clinical perspective, are much more likely to be used.
2.Materialsand Methods
2.1. Intramyocardial Injections. Canine studies were ap-
proved by the Animal Use Subcommittee at the University of
Western Ontario. A total of 19 separate injections of 111In-
tropolone were administered into normal left ventricular
myocardium of 12 healthy female canines (18–25kg). Seven
of 12 canines had 2 injections of 111In-tropolone with at
least 2 weeks separating the last imaging session of the ﬁrst
injectionandtheﬁrst imagingsession orthesecondinjection
which ensured that at least 10 half-lives had passed prior to
the second injection.
In the endocardial group, 111In-tropolone (mean ±
SD: 50.8 ± 12.3MBq; 10 injections) was injected into the
anteroapical wall of the endocardium. In preparation for
injection, canines were induced with propofol followed
by endotracheal intubation and mechanical ventilation
and anesthesia was maintained with isoﬂurane (1.5–2%).
Endocardial injections were performed using the Stiletto
Endomyocardial Injection System (Boston Scientiﬁc, Natick,
MA) and the procedure is described elsewhere [17]. Using a
1 ml syringe containing 111In-tropolone (995ul) and 0.5%
India ink tissue dye to identify injection sites, 8–10 injections
of ∼0.1ml each were delivered to the endocardium using
the catheter (26-gauge needle). Each site of injection was
recorded on transparencies. Following each injection, the
needle and Stiletto catheter were retracted and advanced
into another position, generally within 8–10mm of the
other injections. Within 30–40 minutes of the ﬁrst injection,
canines were transported to the SPECT suite.
In the epicardial group, 111In-tropolone (52.1 ±
21.8MBq; 9 injections; 25-gauge needle) was injected into
the anteroapical wall. Following anesthesia as described
above, a left thoracotomy was performed between the 3rd
and 4th ribs exposing the surface of the heart. Several
(6–10) intramyocardial injections were then performed
with a syringe with a 25-gauge needle containing 1ml of
111In-tropolone (including dye). Within 30 minutes of the
injections, the thoracotomy incision was closed and the
animal was transferred to the SPECT suite for imaging. Vital
signs including heart rate were monitored throughout the
injection and imaging sessions. At the ﬁnal imaging session,
animals were sacriﬁced using a bolus of KCl solution.
2.2. SPECT Acquisition and Analysis. On anesthetized
canines, serial SPECT and wholebody images were acquired
over the ﬁrst 5 hours on injection day using a dual-head
Millennium MG (General Electric, Milwaukee, WI) and
a Symbia T6 SPECT/CT (Siemens, Erlangen, Germany)
equipped with medium energy parallel hole collimators.
Three subsequent SPECT follow-up imaging sessions were
performed weekly over the following 3-4 weeks after the
initial injection. Imaging parameters were as follows: 128
× 128 with 64 projections/head acquired over 180 degrees.
Indium-111 counts were acquired with energy windows
at 171keV and 245keV (±10%) for the GE system and
172keV and 247keV (±7.5%) for the Siemens system, and
the acquisition time/projection angle increased from 30
seconds/projection on injection day to 30, 60, and 120 orInternational Journal of Molecular Imaging 3
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Figure 1: Images of 111In following epicardial delivery into normal myocardium following left thoracotomy. (Left) Sagittal SPECT/CT slice
showingsite of 111In injection in the myocardium. (Right) Wholebody 111In scans of canine demonstrating 111In activity at the injection site
(day 0–15 wholebody scans are scaled to a maximum pixel value).
Day 0 Day 0 Day 7 Day 14 Day 21
Figure 2: Images of 111In following endocardial delivery into normal myocardium with a specialized catheter under ﬂuoroscopic guidance.
(Left) Sagittal slice of SPECT/CT image localizing 111In injection within the myocardium on day of injection. (Right) Wholebody scans of
same canine days 0, 7, 14, and 21 showing 111In within the myocardium (day 0–14 wholebody scans are scaled to a maximum pixel value).
180 seconds/projection at 3 diﬀerent followup time-points,
respectively.Wholebody2Dimageswerealternatelycollected
withSPECToninjectiondayusingthesame energywindows
including one wholebody scan at each imaging follow-up.
Wholebody imaging parameters: 256 × 1024pixel matrix
with 2.26mm/pixel, ﬁxed acquisition time of 23 minutes
for the Millenium camera and 17 minutes for the Symbia
(2.34mm/pixel), and the same 111In energy windows as
SPECT were used.
Volume of interest (VOI) analysis was conducted on
SPECT images that were corrected for background and
subsequentlyreconstructedusing aniterativealgorithm[18].
T h eﬁ r s tS P E C Td a t as e ta c q u i r e d( t = 0) had a VOI deﬁned
as pixels ≥30% ofthe maximum pixel intensity and was used
to create a mask image. This mask was then multiplied by
eachSPECTimage acquiredand themean pixelintensitywas
determined (MATLAB, Mathworks, Natick, MA) [6]. Time
activity curves (TAC) were generated for each injection and
corrected for physical decay. Biexponential functions were ﬁt
to the TACs to determine the short (Ts
1/2) and long (Tl
1/2)
components of 111In clearance from injected myocardium.
Curve coeﬃcients were also normalized to determine the
fraction of the injected activity that cleared with the Ts
1/2 or
Tl
1/2 and were reported as percentages. Heart to whole body
(H:WB) activity ratios were also calculated from region
of interest (ROI) analysis of wholebody scans using GE
software (Xeleris, General Electric, Milwaukee, WI). Regions
of similar area were drawn on wholebody images and counts
derived from these regions were background corrected and
normalized to the total image counts. These ratios were used
for comparison between canines regarding the degree of
radiolabel retention and are reported as a percentage.
For the leakage parameter, Tl
1/2 data from our published
report, which was similarly acquired, was compared to
epicardial injections in this dataset and the combined
epicardial data was compared to the endocardial data to
d e t e r m i n ei ft h e yw e r es i g n i ﬁ c a n t l yd i ﬀerent.
2.3. Statistical Analysis. All statistical analysis was performed
using SPSS 18.0 (SPSS Inc., Chicago, IL) with α set to 0.05.
Non-parametric analysis was used to assess diﬀerences in
the heart:wholebody ratios and Ts
1/2 and Tl
1/2 measurements
using an independent samples test, and multiple pairwise
comparisons were corrected using Bonferroni correction. All
data are reported as the mean ± SEM.
3.Results
3.1. Evaluating Injection Eﬃciency in Canine Myocardium.
The myocardial retention of 111In-tropolone following injec-
tion into canine myocardium was determined from serially4 International Journal of Molecular Imaging
acquired wholebody images, and ratios of heart to whole-
body (H:WB) activity were calculated. Ratios (expressed
as a percentage) were similar with the Epi group and
Endo group having H:WB ratios of 48 ± 5% and 50 ±
4% (P = .902) respectively, directly following injection,
indicating that the endocardial injection was as eﬀective in
tracer delivery as the epicardial injection within the speciﬁed
time window of 30–40 min postinjection. Table 1 shows
the change in ratios for each animal for the ﬁrst 5 hours
following injection. Wholebody images from representative
canines acquired after injection (Day 0 to 3 weeks) show
the localization of 111In within the myocardial tissue as
conﬁrmed by SPECT/CT following epicardial (Figure 1)
and endocardial (Figure 2) injection. Images also show the
biodistributionof 111Inwithintheliver,kidneys,andbladder.
One animal in each of the groups had a lower ratio likely due
to some injections into the left ventricular cavity rather than
myocardium.
3.2. Early and Late Retention of Myocardial 111In: Viable
Cell Leakage. Serial SPECT imaging on the day of injection
followed by images acquired weekly over the subsequent
20–26 days helped to better deﬁne the early washout
phase occurring immediately after the injections and the
longer term retention of 111In within myocardial tissue.
Biologicalhalf-lives generated from ROI analysis and ﬁt with
biexponentialcurves demonstrated Ts
1/2 and Tl
1/2 to be 2.17±
0.42 hours and 1567.07 ± 470.25 hours, respectively, for the
endocardialgroupand 1.77±0.25hoursand1286.09±253.02
hours for the epicardial group. Statistical analysis identiﬁed
thattherewere nosigniﬁcantdiﬀerencesfoundwhentheTs
1/2
(P = .594) and Tl
1/2 (P = 1.00) were compared between
groups. The original, previously reported epicardial estimate
of radiolabel leakage from viable cells was not signiﬁcantly
diﬀerent from additional epicardial experiments (882.7 ±
242.8( s e e[ 6]) hrs versus 1608.8 ±369.5h r s ;P = .166).
Curve ﬁtting parameters are given in Table 2 and TACs
are shown in Figure 3 for all canines. A signiﬁcant diﬀerence
was found between the long and short components for both
endocardial group (P<. 001) and epicardial group (P<
.001). Of the epicardially injected activity that remained
in the myocardium following the ﬁrst SPECT acquisition
approximately 40 minutes after the injection, on average
28% cleared the myocardium with the short half-life while
the remaining 72% cleared with the longer half-life. Of
the endocardial injections, 38% of the activity cleared the
myocardium with the short half-life while 62% cleared with
thelonghalf-life thusindicating thatthemajority ofthelabel
injected was retained within the myocardial cells. Figure 4
conﬁrmsSPECTimages,anddemonstratesmyocardial tissue
injection location as marked by tissue dye.
4.Discussion
Nonspeciﬁc imaging markers used for noninvasive cell
tracking have their own perils. As outlined by Bengel et al.
[19], clinical techniques typically used in understanding cell
biodistribution over the short term prove diﬃculty over the
Epi
Endo









































myocardium. Canines were directly injected with 111In-tropolone
either by endocardial route via catheter (dotted lines) or epicardial
route following thoracotomy (solid lines). Canines were serially
imaged with SPECT on transplantation day with three follow-up
imaging sessions. Region of interest analysis was conducted on
images corrected for physical decay and background and ﬁt to bi-
exponential curves.
longterm (i.e., weeks) as such markers can be susceptible to
instability in the transplanted cell population or re-uptake
of interstitial label into the surrounding tissue or even other
transplantedcellsmakingquantiﬁcationmorediﬃcult.Label
re-uptake has been demonstrated with iron oxide labels
[20, 21] in stem cell transplantation studies, while other
studies indicate SPECT radiolabels like 99mTc-HMPAO [22]
and PET tracers 18F-FDG [23]a n d64Cu-PTSM [24]e ﬄux
rapidly from various populations of viable cells.
In our previous work, we characterized the main sources
of radiolabel loss from canine bone marrow stromal cells
labeled with 111In-tropolone both in vitro and following
injectionthroughtheepicardium.Weidentiﬁedtransplanted
cell death and radiolabel leakage from viable transplanted
cells as main contributors and used their associated 111In
clearancekinetics(Tl
1/2)formodelingtheuseof 111Inas anin
vivo marker of viability. For the determination of radiolabel
leakage in vivo, we injected free 111In-tropolone in situ and
monitored 111In clearance kinetics from endogenous normal
myocardial cells as was done in the experiments reported
here. Zhou et al. state that observed radioactivity cannot
be translated to the number of surviving cells as 111In label
released from dead cells may remain with the cell [25].
However, our model uses convolution as a means to correct
for interstitial label related to death and leakage, and issues
related to interstitial label are tenuous as we have veriﬁed
that the clearance activity from dead cells is short relative
to activity loss from viable cells with the average viable cell
biological clearance ∼79 times longer than that for dead cell
clearance, or DIRF. To be clear, our model that incorporatesInternational Journal of Molecular Imaging 5
Table 1: Heart to wholebody ratios of 111In postinjection (ratios expressed as %).
EPI (%)
D o g 12 3 456789
0 hrs 31.8 19.4 45.3∗ 49.2 62.6 56.4 59.7 57.8 49.5
. . . 29.4 18.3 — 47.6 60.5 53.6 56.9 45.1
. . . — 46.8 55.0 54.1 42.9
. . . 27.9 17.4 — 46.3 59.2 52.5 54.2
. . . — 46.2 57.2 51.4 41.0
5 hrs 26.3 17.1 — 45.5 56.4 51.2 52.5 49.3 39.4
ENDO (%)
D o g 12 3 456789 1 0
0 hrs 22.8 42.9 45.5 44.0 54.1 62.5 60.0 49.2 59.8 57.6
. . . 23.9 40.8 43.2 42.3 52.0 60.3 56.1 47.6 54.4 54.8
. . . 21.3 39.0 40.6 40.9 50.1 59.5 54.0 44.7 50.5 52.5
. . . 20.6 37.9 38.9 48.5 58.4 52.3 43.0 47.2 50.2
. . . 19.9 36.9 37.5 40.1 47.7 57.6 51.4 41.6 44.5 48.4
5 hrs 19.1 36.3 36.8 39.4 46.7 — — — — —
∗Serial wholebody scans not acquired at day 0.
All data acquired over a 5 hr period following injection.
Table 2: Exponential curve ﬁtting parameters.
f(t) = a · exp(−bt) +c ·exp(−dt)
EPI
Dog a† bc ‡ dT s
1/2 (hrs) Tl
1/2 (hrs)
1 37.9 −0.3712 62.1 −0.0012930 1.87 537
2 16.0 −0.4705 84.0 −0.0017590 1.47 394
3 — — 100 −0.0005308 — 1306
4 19.8 −1.004 80.2 −0.0005354 0.69 1295
5 29.2 −0.291 70.8 −0.0003566 2.38 1944
6 29.6 −0.2413 70.4 −0.0002413 2.87 2873
7 29.4 −0.4448 70.6 −0.0008787 1.56 789
8 28.2 −0.4850 71.8 −0.0005060 1.43 1370
9 36.6 −0.3662 63.4 −0.0006483 1.89 1069
71.8 ±2.61 .77 ± 0.25 1286 ± 253
ENDO
1 40.7 −0.3407 59.3 −0.0013530 2.03 512
2 31.5 −0.2468 68.5 −0.0006903 2.81 1004
3 21.8 −2.7770 78.2 −0.0012670 0.25 547
4 29.7 −0.3896 70.3 −0.0006643 1.78 1043
5 33.1 −0.4293 66.9 −0.0004125 1.61 1680
6 49.9 −0.2316 50.1 −0.0007734 2.99 896
7 25.0 −1.1510 75.0 −0.000840 0.60 825
8 37.6 −0.4884 62.4 −0.0001245 1.42 5567
9 63.0 −0.1564 37.0 −0.0003590 4.43 1931
10 51.3 −0.1858 48.7 −0.0004166 3.73 1664
61.6 ±4.12 .17 ± 0.42 1567 ± 470
†Coeﬃcients “a”a n d“ c” normalized to 100%.
‡Dog 3 normalized data not included in fractional washout averages.6 International Journal of Molecular Imaging
(a) (b)
(c) (d)
Figure 4:Digital images ofex vivo myocardialtissue conﬁrmingendocardial (dotted linecircles) and epicardial (solidline circles) injections
with tissue dye in normal tissue of representative canines. As noted during gross examination of the heart, needle punctures identiﬁed
epicardial injection within the region of the left anterior descending coronary artery while endocardial injections were placed closer to the
apex.
these corrections for clearance of cellular debris and leakage
fromviablecellsindicatesthat 111In canbe used to quantitate
cell half-life between 20 hrs and 60 days with the error in
the measurements increasing as the upper and lower bounds
are approached. In vitro work also indicated that dead cell
activity or leaked activity is not taken up by either remaining
viable transplanted cells or resident cardiomyocytes [6].
Additionally, our imaging protocol includes wholebody
imaging to estimate the remaining absolute fraction of
t h ei n j e c t e dd o s ei nm y o c a r d i u m( H : W Br a t i o )a n dt h e
observed Tl
1/2 estimates the biological half-life associated
with viable transplanted cells. Numbers associated with the
surviving fractionas afunctionoftimecanthenbeestimated
providing the minimum cell number remaining, as our
method cannot account for cells that proliferate subsequent
to transplantation. Future work is needed to examine the
robustness of this noninvasive approach to transplanted cell
viability.
In this paper, we have further evaluated the use of the
transendocardial injection technique using 111In-tropolone.
Speciﬁcally, we have shown that the injection eﬃciency and
retention characteristics of 111In-tropolone injected within
normal canine myocardium are independent of the site of
injection (i.e., subepicardium versus subendocardium). This
is evident in the 111In clearance patterns reﬂected by Ts
1/2
and Tl
1/2. In the development of our technique for modeling
111In as an in vivo marker of transplanted cell viability,
comparisons were necessary to demonstrate that diﬀerences
in 111In leakage from myocardium were not injection-site
dependent. Furthermore, we wanted to ensure that intrinsic
diﬀerences between myocardial layers did not signiﬁcantly
aﬀect Ts
1/2 which represents the mechanical loss associated
with intramyocardial injection. Based on these results, it is
expected that retention of endocardially injected cells may
not be signiﬁcantly diﬀerent from those injected epicardially.
Transmuralheterogeneityacrosstheleftventricularheart
wall has been extensively studied in the canine heart and
may have implicationsforcell survival and retention. During
ischemic injury, a well-observed phenomenon is the greater
susceptibility of the subendocardium [26]w h i c hm a yb e
linked to higher oxygen demand within this myocardial
layer [27] making it more vulnerable. Cell transplantation
within peri-infarcted subendocardium with compromised
ﬂow may risk cell survival, and diﬀerent ﬂow patterns may
themselves be a factor inﬂuencing cell clearance. Transmural
intramyocardial pressure and perfusion gradients suggest
higher contractility within the subendocardium with poorer
perfusion [15] relative to the subepicardium in the canineInternational Journal of Molecular Imaging 7
[14, 27, 28] which could aﬀect retention. Lower pressures in
the LV cavity relative to the subendocardium [14]m a ya l s o
result in problems with retention of injected material allow-
ingmorematerial toleakintothecavityand redistributecells
to other organs. Optimization of transendocardial delivery
suggest that parameters like needle length and injection
volumecan improve retention ofvarious injectable materials
[29, 30]. Irrespective oftransmural diﬀerences,ourdatadoes
not suggest diﬀerences in the leakage parameter between
thesubendocardialandsubepicardiallayers.Additionalwork
with 111In labeled cells also support insigniﬁcant diﬀerences
in retention and clearance kinetics in infarcted canine
myocardium [17], but future work would also need to
verify that similar clearance patterns exist for cellular debris
between layers.
The radiotoxic eﬀect of 111In for the purposes of tracking
labeled cells has been previously addressed [31]. Reports
indicate that the labeling mechanism of 111In is that it
binds to cytosolic proteins having little direct contact with
the nucleus [32]. In our study, large doses of 111In were
injected into normal myocardium; however, radiotoxicity
was not expected to be a primary concern considering the
postmitoticnatureoftheadultcaninemyocardium.Previous
workalsoevaluatedthepotentialofﬁbrosisasaresultof 111In
radiotoxicityusing delayed enhancement MRIfollowing Gd-
DTPA administration which was not positive [6].
In summary, we have conﬁrmed the leakage compo-
nent of our model demonstrating 111I nr e t e n t i o ni nv i a b l e
endocardial cells in vivo. The leakage gives the model an
upper half-life limit of approximately 60 days. Eﬃciency of
injections into theepicardium or endocardiumis similar and
physiological diﬀerences between myocardial layers do not
factor into the kinetics of radiotracer clearance supporting
the application of the model following endocardial trans-
plantation.
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